By Mark Melchionna
June 15, 2023 – Using data from a Chinese hospital, researchers from the University of California, Riverside (UCR), found that a mchine learning (ML) approach could assess patient age, weight, and other illnesses…
Continue Reading
Researchers from Boston University have developed a machine learning model to provide personalized hypertension treatment recommendations. The model analyzes patient-specific characteristics and medical history to generate a customized hypertension prescription, suggesting the most appropriate…
Continue Reading
There are surprise profits in an overfunded sector, but then there are funding deals for staffing company Incredible Health ($80m), voice recorder Abridge ($12m), meditation company Interaxxon (Muse Headband) ($9m), medication company Arine ($29)…
Continue Reading
By Shania Kennedy
June 09, 2023 – Boston University (BU) researchers have co-developed a machine learning (ML) model designed to provide personalized hypertension treatment recommendations and assist clinicians with choosing which hypertensive medication may be the…
Continue Reading
Top News
A science advisory group of the American Heart Association says that digital technology can address many of the challenges that are faced by center-based cardiac rehabilitation and care programs.
The authors list available…
Apple has unveiled the watchOS 10, featuring new mental health, vision health, and fitness tools. Users can track emotions and moods, access mental health resources, and measure time spent outdoors. The update includes cycling-focused…
Continue Reading
The Medical Board of Australia, which is responsible for regulating medical practitioners in the country, has made some revisions to its telehealth guidelines.WHAT IT’S ABOUT
A major change in the guidelines discourages the practice of prescribing…
Penn Medicine has introduced an AI chatbot named “Penny” to enhance cancer care. Patients exchanged nearly 4,000 medication-related text messages with Penny, with an accuracy rate of approximately 93%. Patient engagement for symptom assessment…
Continue Reading
Mark Cuban Cost Plus Drug Company (MCCPDC) announced it is working with global biosimilar company Coherus Biosciences, Inc. to sell Yusimry, a biosimilar version of the top-selling drug Humira, at a discounted price. Yusimry is…
Continue Reading
Mark Cuban Cost Plus Drug Company (MCCPDC) announced it is working with Coherus Biosciences, Inc. to sell Yusimry, a biosimilar version of the top-selling drug Humira, at a discounted price. Yusimry is used to treat…
Continue Reading
